JP2019527204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527204A5 JP2019527204A5 JP2018567892A JP2018567892A JP2019527204A5 JP 2019527204 A5 JP2019527204 A5 JP 2019527204A5 JP 2018567892 A JP2018567892 A JP 2018567892A JP 2018567892 A JP2018567892 A JP 2018567892A JP 2019527204 A5 JP2019527204 A5 JP 2019527204A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- immunoreceptor
- individual
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 11
- 238000009175 antibody therapy Methods 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims 3
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims 3
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims 3
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102000004207 Neuropilin-1 Human genes 0.000 claims 2
- 108090000772 Neuropilin-1 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 2
- 108091008915 immune receptors Proteins 0.000 claims 2
- 102000027596 immune receptors Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- -1 CD79b Proteins 0.000 claims 1
- 108091008928 CXC chemokine receptors Proteins 0.000 claims 1
- 102000054900 CXCR Receptors Human genes 0.000 claims 1
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100035486 Nectin-4 Human genes 0.000 claims 1
- 101710043865 Nectin-4 Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108091007561 SLC44A4 Proteins 0.000 claims 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710170091 Transmembrane glycoprotein NMB Proteins 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 125000005629 sialic acid group Chemical group 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357653P | 2016-07-01 | 2016-07-01 | |
| US62/357,653 | 2016-07-01 | ||
| PCT/US2017/040483 WO2018006066A1 (en) | 2016-07-01 | 2017-06-30 | Inhibitory immune receptor inhibition methods and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527204A JP2019527204A (ja) | 2019-09-26 |
| JP2019527204A5 true JP2019527204A5 (enExample) | 2020-08-06 |
Family
ID=60787693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567892A Pending JP2019527204A (ja) | 2016-07-01 | 2017-06-30 | 抑制性免疫受容体阻害方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190300606A1 (enExample) |
| EP (1) | EP3478315A4 (enExample) |
| JP (1) | JP2019527204A (enExample) |
| CN (1) | CN109414490A (enExample) |
| AU (1) | AU2017290884A1 (enExample) |
| CA (1) | CA3026588A1 (enExample) |
| WO (1) | WO2018006066A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116003596A (zh) | 2015-10-29 | 2023-04-25 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| US11965188B2 (en) | 2018-01-03 | 2024-04-23 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| WO2019200462A1 (en) * | 2018-04-16 | 2019-10-24 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
| KR20210141447A (ko) | 2018-12-26 | 2021-11-23 | 실리오 디벨럽먼트, 인크. | 항-ctla4 항체 및 이의 사용 방법 |
| US20220387616A1 (en) * | 2019-07-03 | 2022-12-08 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| BR112021026789A2 (pt) * | 2019-07-03 | 2022-05-10 | Palleon Pharmaceuticals Inc | Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas |
| PH12022551035A1 (en) | 2019-11-04 | 2023-06-14 | Alector Llc | Siglec-9 ecd fusion molecules and methods of use thereof |
| WO2021231893A1 (en) * | 2020-05-15 | 2021-11-18 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compounds for inhibiting ly6k and methods of using same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2292264A3 (en) * | 2003-07-24 | 2012-12-19 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| SI3508502T1 (sl) * | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| US20170216403A1 (en) * | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| KR102485788B1 (ko) * | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| WO2016038064A1 (en) * | 2014-09-10 | 2016-03-17 | Innate Pharma | Cross reactive siglec antibodies |
| KR20170072343A (ko) * | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
-
2017
- 2017-06-30 CA CA3026588A patent/CA3026588A1/en active Pending
- 2017-06-30 US US16/307,428 patent/US20190300606A1/en not_active Abandoned
- 2017-06-30 EP EP17821423.5A patent/EP3478315A4/en not_active Withdrawn
- 2017-06-30 AU AU2017290884A patent/AU2017290884A1/en not_active Abandoned
- 2017-06-30 CN CN201780039931.4A patent/CN109414490A/zh active Pending
- 2017-06-30 JP JP2018567892A patent/JP2019527204A/ja active Pending
- 2017-06-30 WO PCT/US2017/040483 patent/WO2018006066A1/en not_active Ceased
-
2021
- 2021-07-02 US US17/366,512 patent/US20220169724A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527204A5 (enExample) | ||
| Jiang et al. | Targeting CD47 for cancer immunotherapy | |
| Tai et al. | B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma | |
| Harris et al. | Immuno-oncology combinations: raising the tail of the survival curve | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| Bonavida | Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Kohrt et al. | Targeting CD137 enhances the efficacy of cetuximab | |
| JP2017509342A5 (enExample) | ||
| EP4275702A2 (en) | Cd70 combination therapy | |
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
| Duarte et al. | Gastric cancer: basic aspects | |
| JP2016187356A5 (enExample) | ||
| JP2014512812A5 (enExample) | ||
| Ochi et al. | Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2017513478A5 (enExample) | ||
| ES2909014T3 (es) | Composiciones y métodos para modular una respuesta inmunitaria | |
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| JP2017515792A5 (enExample) | ||
| Bhutani et al. | Monoclonal antibodies in oncology therapeutics: present and future indications | |
| JP2015508816A5 (enExample) | ||
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| JP2017537972A5 (enExample) | ||
| JP2018537536A5 (enExample) |